Loading organizations...
Loading organizations...
Truveris is a technology company dedicated to optimizing the prescription drug ecosystem. They build sophisticated software platforms designed to enhance transparency, efficiency, and cost management within pharmacy benefits. Their solutions streamline the entire pharmacy benefits plan lifecycle, providing critical data and analytical tools to understand drug pricing, utilization patterns, and overall spend.
The company was founded in 2009 by Anthony Loiacono, Justin Greene, and Leon Greene. The founders recognized the significant opaqueness and inefficiencies inherent in the pharmacy benefits space. Their core insight was that technology could demystify complex prescription drug costs and processes, leading to more informed decision-making and ultimately, more affordable and accessible medication for patients.
Truveris serves various stakeholders in the healthcare industry, including health plans, employers, and benefit consultants, who seek to improve their pharmacy programs. The company's vision is to foster complete truth and clarity across the pharmacy landscape, equipping clients with the necessary intelligence to navigate complexities and drive meaningful improvements in prescription drug access and affordability.
Truveris has raised $67.0M across 5 funding rounds.
Truveris has raised $67.0M in total across 5 funding rounds.
Truveris has raised $67.0M in total across 5 funding rounds.
Truveris's investors include Stephen Bloch, Vijay Lathi, B Capital Group, Canaan Partners, Tribeca Venture Partners, Tom Rodgers, Angelic Ventures, Bond, CapitalG, Innovation Endeavors, Principia Growth Equity, Trajectory Ventures.
Truveris is a healthcare technology company that builds a proprietary, data-driven platform to optimize pharmacy benefits for self-insured employers and benefits consultants. It serves over 800 clients by replacing traditional pharmacy benefit manager (PBM) models with transparent procurement, 100% claims analysis, contract compliance monitoring, and member engagement tools, solving the problem of escalating pharmacy costs through competition, insights, and oversight.[1][2][4] The platform has analyzed over 10 million claims, managed more than $10 billion in drug spend, and delivered $7 billion in savings via improved deals, with recent $15 million Series E funding fueling operational growth amid rising focus on PBM transparency.[1][4]
Founded 15 years ago (around 2010), Truveris emerged to address opacity in pharmacy benefit management, a major cost driver for employers.[2] Specific founders are not detailed in available sources, but the company was built by pharmacy experts aiming to introduce data-led transparency and accountability.[1][2] Early traction came from its tech platform disrupting PBM contracting, attracting investors like Canaan Partners and New Leaf Venture Partners, who highlighted its focus on pharmacy spend challenges; a pivotal $15 million Series E round underscored validation from existing backers for scaling nationwide.[1] Over time, it grew to a team of 100+ experts, partnering with consultants for 10+ years and expanding into claims analytics and GLP-1 drug management.[2][4][7]
Truveris rides the wave of PBM reform and pharmacy cost transparency trends, amplified by skyrocketing GLP-1 drug demand (e.g., semaglutide/tirzepatide), where claims rose sharply from 2023-2025, straining plans and exposing mismanagement.[1][7] Timing aligns with regulatory scrutiny on PBM practices and employer demands for fiduciary compliance, positioning Truveris as a neutral overseer in a $500B+ U.S. pharmacy market.[1] It influences the ecosystem by empowering self-insured employers (covering ~65% of workers) with tools for competition and audits, fostering efficiency, affordability, and access amid digital health shifts toward SaaS analytics.[3][5]
Truveris is poised for expansion with fresh Series E capital, likely deepening AI-driven predictive analytics, GLP-1 audits, and microservices scalability to capture more of the self-insured market.[1][3][7] Trends like PBM consolidation, GLP-1 cost surges (18% YoY diabetes med growth in some clients), and demands for real-time transparency will propel growth, potentially evolving it into a full-stack pharmacy intelligence leader.[7] As healthcare tech prioritizes outcomes over opacity, Truveris' model—proven at $7B savings—could redefine employer control, sustaining its edge in reducing pharmacy spend nationwide.[4]
Truveris has raised $67.0M across 5 funding rounds. Most recently, it raised $15.0M Series E in May 2024.
